Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) for the reporting period ending December 29, 2016. The filing reports a significant legal event involving a lawsuit filed by ChromaDex against Elysium Health, Inc. in the United States District Court for the Central District of California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal contingency rather than periodic financial performance.
Material Changes and Legal Action
On December 29, 2016, ChromaDex filed a complaint alleging multiple breaches of contract by Elysium Health, Inc. The material allegations include:
- Breach of pTeroPure Supply Agreement: Failure to make payments for purchases of pTeroPure pterostilbene under the agreement dated June 26, 2014.
- Breach of NIAGEN Supply Agreement: Failure to make payments for purchases of NIAGEN nicotinamide riboside under the agreement dated February 3, 2014.
- Breach of Trademark License Agreement: Failure to pay royalties due under the agreement dated February 3, 2014.
- Fraudulent Inducement: Allegations that certain Elysium officers made false promises to induce ChromaDex to provide large supplies of the aforementioned products.
ChromaDex is seeking punitive damages, money damages, and interest.
Outlook, Risks, and Contingencies
The primary risk disclosed is the outcome of the pending litigation. The filing incorporates the full text of the Complaint as Exhibit 99.1. No forward-looking guidance or management commentary regarding future financial performance is included in this specific report.
Investor Verification Checklist
- Verify the status of the lawsuit filed in the Central District of California against Elysium Health, Inc.
- Review the attached Complaint (Exhibit 99.1) for specific monetary amounts claimed.
- Assess the potential impact of the alleged payment defaults on ChromaDex's future cash flows and revenue recognition.
- Monitor for any counterclaims or settlement negotiations between ChromaDex and Elysium.